



THE HODGKIN LYMPHOMA MRD CONSORTIUM FOUNDATION
Board: Anton Hagenbeek, M.D., Ph.D. (chairman), Amsterdam; Andreas Engert, M.D., Ph.D.,
Cologne; John Radford, M.D., Ph.D., Manchester

Activities of the MRD consortium in 2018-2019.

The MRD consortium project started with an investigator-initiated grant “Evaluation of minimally invasive molecular methods for detection of Minimal Residual Disease in Hodgkin Lymphoma”, which commenced in 2018. Next meeting was held at the ISHL 11 in Cologne on Monday 29th October, 2018. Attendees of this meeting were Anton Hagenbeek, Ralf Küppers, Arjan Diepstra, Anna Sureda, Andreas Engert, John Radford, Ashish Gautam, Sven Borchmann, Michiel Pegtel, Josee Zijstra, Mark Hertzberg, Maher Gandhi and Melita Cirillo. Discussions concerned the optimal SOP for prospective patient sample collections and samples distributions and retrospective sample collections and pre-analytical requirements were discussed. Updates from research activities of all sites were presented. Agreed was that prospective samples from current clinical trials should be preferred. The optimal type of study was debated as the group felt an enrichment for relapsed patients (i.e. in second line clinical trials) would be most useful for the purpose of MRD detection.

1. Amsterdam TH has 60 patients in prospective study that might be suitable, to communicate with SB/MP.
2. Spain - ABVD vs EscBEACOPP recruiting study AS to check suitability.
3. France - no current relapse or first line study at present. BREACH study closed.
4. ALLG (Australia) - upcoming RADAR and RATHAL follow-up samples. MH to consider suitability.
5. UK - RADAR study in early disease might be suitable. TRANSFORM is a follow up study after therapy with time points for sample collection. JR to consider suitability.
6. EORTC study - BV in ABVD lead by Martin Hutchings - AS to discuss if this is also suitable.

A second meeting was held in Lugano on 18-06-2019. Attendees were A. Engert, C.Keane, M. Ghandi, R. Küppers, M. Cirillo, S. Borchmann and A. Sureda. Apologies: Michel Pegtel (MP), Ester Drees (ED), Arjan Diepstra (AD), Ton Hagenbeek (TH), Josee Zijlstra (JZ) and Athanasios Zomas (Takeda). In the following grant period the members aim to address experimentally outstanding questions related to MRD detection in HL. In 2019 a next meeting was held in June 13th in Amsterdam UMC to discuss progress on the technical hurdles of the various techniques in detecting MRD. The attendees of this meeting were Ana Sureda, Michiel Pegtel, Andreas Engert, Ton Hagenbeek, Arjan Diepstra, Josee Zijlstra Melita Jagiello, Sven Borchmann and Esther Drees, Takeda Representative was Dr. Athanasios. Members presented their work and future collaborations discussed as to how data can be compared. The next meeting planned at ISHL 2019 was postponed due to COVID-19.